Interpace Diagnostics Group, Inc. Initiates A Partnering Arrangement with Dianon Systems Inc. and Certain Regional Labs to Provide Customers with a One-Stop Service for Molecular Testing for Indeterminate Thyroid Nodules
January 22, 2019 at 06:55 am EST
Share
Interpace Diagnostics Group, Inc. announced that it has finalized the validation of its third specimen type for its molecular thyroid tests ThyGeNEX™ and ThyraMIR®. Interpace has expanded its services again to now also process specimens prepared in formalin fixed, paraffin-embedded (FFPE) samples. Prior to this validation, ThyGeNEXT and ThyraMIR the company is the only marketed molecular products validated with both RNARetain® and cytology slides. The company initiated a partnering arrangement with the Dianon Systems Inc. division of LabCorp and certain regional labs to provide customers with a one-stop service for molecular testing for indeterminate thyroid nodules. Interpace’s validation of cytology slides led to further expansion of its thyroid business in 2018 with former Rosetta Genomics customers when Rosetta filed for Chapter 7 bankruptcy. Interpace now offers the most expansive set of choices with the FFPE sample expansion of specimen options, enabling it to be flexible and responsive to all of its customers’ needs. This also provides an opportunity for further growth as those physicians, who use alternate providers, find this level of customization best suited to the manner in which they manage these specimens and patients in their practices.
Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.
Interpace Diagnostics Group, Inc. Initiates A Partnering Arrangement with Dianon Systems Inc. and Certain Regional Labs to Provide Customers with a One-Stop Service for Molecular Testing for Indeterminate Thyroid Nodules